We have long been sanguine that Merck would get well into the 2030s with Keytruda® on patent. Now it seems 2040 may be reachable. Again, this is good news for a stable cash flow model, at Merck, as pembrolizumab now accounts for close to one third of all sales. The new patents would cover a delivery under the skin rather than via an I.V. line. Here's that, from Reuters:
. . .Merck's patents on the subcutaneous version of Keytruda could protect that formulation until at least 2040, according to Tahir Amin, co-founder of drug patents watchdog group Initiative for Medicines, Access & Knowledge (I-MAK). . . .
Yep -- now you know. . . with an older vintage graphic, solely for expediency. . . feeling rather. . . lazy, today. Smile.
नमस्ते
1 comment:
Once more, at 8:52 pm… smiling.
Post a Comment